A new vaccinia virus, acting as both an oncolytic and anti-angiogenic agent, can enter and kill triple-negative breast cancer cells and could lead to a more targeted therapy against this deadly form of breast cancer, according to new research.
A new vaccinia virus, acting as both an oncolytic and anti-angiogenic agent, can enter and kill triple-negative breast cancer cells and could lead to a more targeted therapy against this deadly form of breast cancer, according to new research.